Samsung Bio “Considering expansion of 6th factory with completion goal of 2027”

Samsung BioLogics announced its vision to become a global top-tier bio company by leveraging its production capacity, business portfolio, and geographical base. To this end, the plan is to expand the 6th factory with the goal of completion in 2027 and increase production capacity to 964,000 liters.

Jon Lim, CEO of Samsung BioLogics, said at the 2025 JP Morgan Healthcare Conference held in San Francisco, California, USA on the 14th (local time), “Despite the difficult business environment in 2024, Samsung BioLogics maintained solid growth through the 4Es,” adding, “5 in 2025.” “We will continue to grow through the completion of the factory and the start of antibody/drug conjugate (ADC) production,” he said. The 4Es are the values ​​that Samsung BioLogics executives and employees should pursue, meaning ▲customer satisfaction, ▲excellent operational efficiency, ▲highest quality, and ▲outstanding employee capabilities.

The JPM Healthcare Conference is the world’s largest pharmaceutical and bio investment event held every January. Samsung BioLogics held a corporate presentation at the main event venue, ‘Grand Ballroom’ again this year. The Grand Ballroom is a stage where only 27 companies selected among the 550 officially invited companies can make presentations. Continuing from last year, the presentation order was also assigned to the second day of the event along with global big pharma companies such as GlaxoSmithKline, Eli Lilly, and AstraZeneca.

In this announcement, CEO Jon Lim first presented the highest ever annual performance and orders as the major achievements of last year. He said, “The amount of orders received in 2024 has exceeded 5 trillion won, and the accumulated orders to date have exceeded $17.6 billion (approximately 25 trillion won).” He added, “Annual sales in 2024 are also expected to increase by 15-20% compared to the previous year, which is the year of listing. “This is about 15 times the growth in sales (KRW 294.6 billion) in 2016,” he explained. The company added that this is being supported by preemptive production capacity expansion.

Samsung BioLogics plans to continue its growth by accelerating its expansion strategy on three major axes: production capacity, business portfolio, and geographic base.

In terms of production capacity expansion, construction of a second bio campus is scheduled to be completed by 2032 to proactively respond to customer demands. To this end, a blueprint for the start of construction of the 6th factory, scheduled for completion in 2027, was also presented. When completed at the same 18 liter scale as Plant 5, the total production capacity is expected to be 964,000 liters, maintaining the world’s No. 1 level. However, the expansion of the 6th factory is still under review, and the final decision on whether to start construction will be confirmed through discussions with the board of directors.

In terms of portfolio expansion, the production area will be expanded from the existing antibody (mAb), finished drug (DP), and messenger ribonucleic acid (mRNA) fields to ADC (antibody drug conjugate). In particular, the plan is to establish a dedicated line for ADC DP by the first quarter of 2027, and to build a fully automated pre-filled syringe (PFS) production facility in October to respond to demand in the Asian market, further enhancing the competitiveness of finished pharmaceutical products. .

In terms of geographical base expansion, we plan to open a sales office in Tokyo, Japan to expand the scope of orders beyond the global top 20 to the top 40 companies. Through this, we will further strengthen our cooperative relationships with Asian customers such as Japan.

CEO Jon Lim said, “To strengthen future growth engines, we will continue to make preemptive and bold investments in line with Samsung’s bio business vision and roadmap,” adding, “We will achieve ‘Vision 2030’ of becoming a top-tier bio company in the industry based on the 4Es.” “I will do my best in 2025,” he said.